Previous close | 0.0800 |
Open | 0.0400 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 170.00 |
Expiry date | 2024-06-28 |
Day's range | 0.0400 - 0.1200 |
Contract range | N/A |
Volume | |
Open interest | N/A |
In the last year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a substantial stake in the company which may have...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
Moderna (MRNA) concluded the recent trading session at $137.90, signifying a -1.52% move from its prior day's close.